PCVX Q4 2025 Earnings — Vaxcyte, Inc. Revenue & Financial Results | Market Cap Arena

PCVXVaxcyte, Inc.

$9B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$5M

Operating Income

-$274M

Net Income

-$247M

EPS (Diluted)

$-1.81

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$225M

Free Cash Flow

-$219M

Stock-Based Comp.

$36M

Balance Sheet

Total Assets

$3.0B

Total Liabilities

$360M

Stockholders' Equity

$2.7B

Cash & Equivalents

$174M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$5M	$0	—
Operating Income	-$274M	-$162M	-69.1%
Net Income	-$247M	-$137M	-79.8%